Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1 (Q24534620)

From Wikidata

Revision as of 20:34, 15 March 2019 by XabatuBot (talk | contribs) (‎Added [ast] label: Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1 (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

infectious disease

0 references

author name string

Julie M Strizki

1

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Cecile Tremblay

2

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Serena Xu

3

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Lisa Wojcik

4

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Nicole Wagner

5

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Waldemar Gonsiorek

6

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

R William Hipkin

7

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Chuan-Chu Chou

8

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Catherine Pugliese-Sivo

9

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Yushi Xiao

10

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Jayaram R Tagat

11

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Kathleen Cox

12

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Tony Priestley

13

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Steve Sorota

14

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Wei Huang

15

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Martin Hirsch

16

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Gregory R Reyes

17

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Bahige M Baroudy

18

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

language of work or name

0 references

publication date

1 December 2005

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Antimicrobial Agents and Chemotherapy

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

49

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

4911-4919

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1315929

24 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1315929

24 March 2017

Virus entry as a target for anti-HIV intervention

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1315929

24 March 2017

SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1315929

24 March 2017

Discovery of 4-[(Z)-(4-bromophenyl)- (ethoxyimino)methyl]-1'-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4'-methyl-1,4'- bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1315929

24 March 2017

Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1315929

24 March 2017

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1315929

7 April 2017

Antiviral activity and safety of 873140, a novel CCR5 antagonist, during short-term monotherapy in HIV-infected adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1315929

27 September 2017

Acquired QT interval prolongation and HERG: implications for drug discovery and development

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1315929

27 September 2017

Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1315929

27 September 2017

The current status of, and challenges in, the development of CCR5 inhibitors as therapeutics for HIV-1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1315929

27 September 2017

Resistance to enfuvirtide, the first HIV fusion inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1315929

27 September 2017

Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1315929

27 September 2017

A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1315929

27 September 2017

Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1315929

27 September 2017

Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1315929

27 September 2017

Piperazine-based CCR5 antagonists as HIV-1 inhibitors. I: 2(S)-methyl piperazine as a key pharmacophore element

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1315929

27 September 2017

Protein design of an HIV-1 entry inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1315929

27 September 2017

HIV-1 membrane fusion: targets of opportunity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1315929

27 September 2017

A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1315929

27 September 2017

Estimating HIV-1 drug resistance in antiretroviral-treated individuals in the United Kingdom

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1315929

29 November 2018

Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1315929

29 November 2018

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1315929

29 November 2018

Human interferon-inducible 10-kDa protein and human interferon-inducible T cell alpha chemoattractant are allotopic ligands for human CXCR3: differential binding to receptor states.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1315929

29 November 2018

Identifiers

10.1128/AAC.49.12.4911-4919.2005

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24534620&oldid=884027724"